Psychopharmacological treatment in COVID-19 pandemic

Creative Commons License

TATLI S. Z., Cakar G., ÇOLAK B., ÖZEL KIZIL E. T.

KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY, cilt.23, ss.52-66, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 23
  • Basım Tarihi: 2020
  • Doi Numarası: 10.5505/kpd.2020.56823
  • Dergi Adı: KLINIK PSIKIYATRI DERGISI-TURKISH JOURNAL OF CLINICAL PSYCHIATRY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, Psycinfo, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.52-66
  • Anahtar Kelimeler: COVID-19 drug treatment, psychotropic drugs, drug interactions, ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY, INTERSTITIAL LUNG-DISEASE, RHEUMATOID-ARTHRITIS, DOUBLE-BLIND, IN-VITRO, HYDROXYCHLOROQUINE, OSELTAMIVIR, AZITHROMYCIN, FAVIPIRAVIR, TOCILIZUMAB
  • Ankara Üniversitesi Adresli: Evet

Özet

The COVID-19 infection is still active both worldwide and in our country. Hereafter, it is going to have marked effects on clinical psychiatric practice. So, it is very important to consider the interactions of psychotropic drugs used in the COVID-19 pandemic in patients receiving psychiatric treatment or planned to start psychiatric treatment. There is still no cure for COVID-19 infection and treatment algorithms change over time. Moreover, studies on drug interactions between the drugs used in COVID-19 treatment and psychotropic drugs to guide the clinician are limited. In this regard, it is thought that it is important for psychiatrists to keep up with the current literature knowledge while planning psychotropic medication during the pandemic process, which is expected to continue for a long time. In this article, the mechanisms of action and interactions of frequently used drugs in the treatment of COVID-19 with psychotropic drugs such as hydroxychloroquine, favipiravir, oseltamivir, remdesivir, tocilizumab and azithromycin are reviewed. Also regardless of drug interactions, the antiviral effects of chlorpromazine and lithium and their place in the potential treatment of COVID-19 are mentioned and potential problems that psychiatric therapies may cause in these patients are discussed.